Table 3.
Authors | Platform | Cells | Findings |
---|---|---|---|
Mao et al (2003) | Genomic microarray | MF/SS | RAF1 (3p25), CTSB (8p22),PAK1 (11q13) JUNB (19p13) increased in MF. FGFR1 (8p11), PTPN1 (20q13) and BCR (22q11) in SS |
Van Doorn et al (2005) | Epigenetic CGH | MF/SS | BCL2 hypermethylated, TP73 (p73), CDKN2A (p16), CDKN2B (p15), CHFR, ACS (TMS1) methylated |
Vermeer et al (2008) | CGH | SS | Gain of MYC, STAT3. Loss of MYC antagonist MXI1 and MNT, ZEB1, DUSP5. |
Caprini et al (2009) | CGH, SNP | SS | Loss 17, BAG4, BTRC, NKIRAS2, PSMD3, TRAF2 |
Van Doorn et al (2009) | Array CGH | MF skin | Gain 7q36, 7q21, loss 5q13, 9p21, FASTK and SKAP1 gained. MF differs from SS in chromosomal alteration. 9p21, 8q24, 1q21 associated with poor prognosis. |
Laharanne et al (2010) | CGH | MF/SS | MF-Gain 1q 7p or 7q. Loss 9p21. SS show 8q and 17q gain. 10p and 17p losses. |
Ballabio et al (2010) | MicroRNA array | SS | Most MIR decreased. 10 MIR discriminatory. Increased-MIR145, MIR574, MIR200, MIR199A, MIR143. Decreased MIR223, MIR342, MIR150, MIR24-1, MIR186 |
Narducci et al (2011) | MicroRNA array | SS | MIR21, MIR486 and MIR214 upregulated in SS |
Van Kester et al (2011) | MicroRNA array | MF | MIR155 and MIR92A increased in tumour. MIR93 highest. Different from MIR in SS. |
SS, Sezary Syndrome; MF, Mycosis Fungoides; CGH, comparative genomic hybridization; SNP, single nucleotide polymorphism